PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING WHERE THERE IS NO PACKAGE LEAFLET, i.e. Combined label and package leaflet {NATURE/TYPE}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ventipulmin Granules 16 micrograms/gram.

2. COMPOSITION

Each gram contains:

Active substances:
Clenbuterol hydrochloride 16 micrograms

Excipients:

Qualitative composition of excipients and other constituents
Mannitol
Lactose Monohydrate
Maize Starch, Dried
Povidone
Maize Starch, Soluble

White, finely grained free flowing granules.

3. PACKAGE SIZE

500 g.

4. TARGET SPECIES

Horses.

5. INDICATIONS FOR USE

Indications for use

Treatment of respiratory disease in horses where airway obstruction due to bronchospasm and/or accumulation of mucus is a contributing factor, and improved mucociliary clearance is desirable. To be used alone or as adjuvant therapy.

In particular :

i) Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospasm or cause airway obstruction and thus an increase in airway resistance. For example, bronchitis, bronchiolitis and bronchopneumonia alone, or associated with equine influenza and other viral respiratory diseases.
ii) Acute, sub-acute and chronic respiratory allergies.
iii) Chronic Obstructive Pulmonary Disease (COPD) in horses.

In cases complicated by the presence of micro-organisms the simultaneous use of antimicrobial agents is indicated.

6. CONTRAINDICATIONS

Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in horses with known cardiac disease.

7. SPECIAL WARNINGS

Special warnings

Special warnings:

None

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
This veterinary medicinal product contains clenbuterol, a beta-agonist. Take care to avoid skin contact. In case of skin contact, wash affected area thoroughly. If irritation occurs/persists seek medical advice. Take care to avoid accidental eye contact. In the case of accidental eye contact, flush thoroughly with clean water and seek medical advice and show the package leaflet or label to the physician. When using do not eat, drink or smoke. After use, wash any contaminated skin immediately with soap and clean water. Avoid inhaling dust.

Pregnancy:
If used during pregnancy, treatment must be discontinued at the expected time of delivery, since uterine contractions may be abolished under its influence.

Interactions with other medicinal products and other forms of interaction:
This veterinary medicinal antagonises the effects of prostaglandin F2-alpha and oxytocin.
This veterinary medicinal is antagonised by β-adrenergic blocking agents.

Overdose:
Dosages of clenbuterol hydrochloride up to 4 times the therapeutic dose (administered orally) for a period of 90 days caused transient side effects typical for beta2-adrenoceptor agonists (sweating, tachycardia, muscle tremor), which required no treatment.

In case of accidental overdose, a β-blocker (such as propranolol) may be used as antidote.

Major incompatibilities:
Not applicable.

8. ADVERSE EVENTS

Adverse events

Horses:

Rare (1 to 10 animals / 10,000 animals treated):	Restlessness[1], Hypotension (Low blood pressure)[1, 2], Tachycardia (Increased heart rate)[1], Muscle tremor[1], Increased sweating[1, 3]

[1]Typical for beta-agonists.
[2]Slight.
[3]Mainly neck region.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed on this label, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details on this label, or via your national reporting system at: Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine

e-mail: adverse.events@vmd.gov.uk

9. DOSAGE FOR EACH TARGET SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Dosage for each species, routes and method of administration

For oral use.
Administer 5 g of the veterinary medicinal product per 100 kg bodyweight twice daily.

This is equivalent to twice daily administration of 0.8 micrograms clenbuterol per kg bodyweight.'

10. ADVICE ON CORRECT ADMINISTRATION

Advice on correct administration

The granules should be added to the feed.
Add to feed immediately before administration. Discard any remaining medicated feed.

A measuring scoop is provided with the 500g pack. When full, the scoop contains 10g. A second line on the scoop indicates a half measure (5g)

11. WITHDRAWAL PERIODS

Withdrawal periods

Meat and offal: 28 days.

Not authorised for use in animals producing milk for human consumption.

12. SPECIAL STORAGE PRECAUTIONS

Special storage precautions

Do not store above 30 °C.
Protect from light.
Discard unused material.
Add to feed immediately before administration.
Discard remaining medicated feed.

13. SPECIAL PRECAUTIONS FOR DISPOSAL

Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

14. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

15. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 08327/5058

Pack sizes

500 g

Not all pack sizes may be marketed.

16. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

17. CONTACT DETAILS

Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:
Boehringer Ingelheim Animal Health UK Limited
Ellesfield Avenue
Bracknell
Berkshire
RG12 8YS, UK
Tel: +44 1344 746957

Manufacturer responsible for batch release:
Klocke Pharma Service GmbH
Strassburger Strasse 77
D- 77767 Appenweier
Germany

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder listed below.

18. OTHER INFORMATION

Other information

POM-V

Gavin Hall
Approved: 03 November 2026